NCT05381090

Circulating Ghrelin as a Biomarker for Dementia

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Swansea University · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study will explore whether circulating acyl-ghrelin (AG) and unacylated-ghrelin (UAG) are reduced in neurodegenerative disease associated with cognitive impairment. It will focus on validating pilot data generated following the analysis of Parkinson's disease (PD), Parkinson's disease dementia (PDD) and healthy cohorts (IRAS project ID: 250933). In addition to the advantages of study replication we will extend the analysis to include two further patient groups that are associated with cognitive impairments, namely, Alzheimer's dementia (AD) and dementia with Lewy bodies (DLB). This study will increase confidence in the replication of our findings. This will be a cross-sectional study using peripheral venous blood.

Conditions

• Dementia

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Venous blood collection	Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.

Timeline

• Start date: 2022-08-15
• Primary completion: 2024-09-01
• Completion: 2024-09-01
• First posted: 2022-05-19
• Last updated: 2023-10-26

Locations

1 site across 1 country: United Kingdom